Poor clinical outcomes observed in MASLD patients with 1-hr plasma glucose over 8.6mmol/L, reveals study

The retrospective enrollment was conducted from June 2009 to May 2024 for consecutive participants with imaging evaluations of fatty liver and a 75-g oral glucose tolerance test. Of these, 1154 participants had MASLD, 161 met the diagnostic criteria for nonalcoholic fatty liver disease but not MASLD (NAFLD-non-MASLD), and 1026 subjects had non-fatty liver.

When compared to patients with non-fatty liver, individuals with MASLD or NAFLD-non-MASLD expressed higher 1-h PG levels. The probability of moderate-to-severe steatosis, ALT elevation, advanced fibrosis (p = 0.03), and cardiovascular illnesses was linked to 1-h PG ≥ 8.6 mmol/L in individuals with MASLD or NAFLD-non-MASLD. Also, the frequency of advanced fibrosis was greater in NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L than in MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (p < 0.05).

In the patients with NAFLD-non-MASLD, 1-h PG≯≥ 8.6 mmol/L was found to be a risk factor for clinical outcomes such liver fibrosis and CVD. Because 1-h PG levels are predictive of clinical outcomes in individuals with MASLD, the findings suggest that they should be regarded as an independent diagnostic indicator.

Soure:

Teng, L., Luo, L., Sun, Y., Wang, W., Dong, Z., Cao, X., Ye, J., & Zhong, B. (2024). Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD. In Diabetes Research and Clinical Practice (p. 111973). Elsevier BV. https://doi.org/10.1016/j.diabres.2024.111973